Comparative Pharmacology
Head-to-head clinical analysis: PARASAL SODIUM versus TRECATOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARASAL SODIUM versus TRECATOR.
PARASAL SODIUM vs TRECATOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Parasal sodium is a prodrug that is converted to 5-aminosalicylic acid (5-ASA) in the colon, where it inhibits cyclooxygenase and lipoxygenase pathways, reducing prostaglandin and leukotriene synthesis, thereby exerting anti-inflammatory effects in the gastrointestinal tract.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the formation of the initiation complex and causing misreading of mRNA.
300 mg orally twice daily
15-20 mg/kg/day orally once daily; maximum 1 g/day.
None Documented
None Documented
2-3 hours for low doses (antiplatelet effect); 15-30 hours for high doses (anti-inflammatory), increasing with dose due to saturation of hepatic metabolism.
Terminal elimination half-life: 8-12 hours in adults with normal renal function; prolonged in hepatic impairment; clinically relevant for once-daily or thrice-weekly dosing
Primarily renal (90-95% as unchanged drug and metabolites, with 50-70% as unchanged salicylate in alkaline urine); minor biliary (2-5%) and fecal (<1%).
Renal: 70-80% as unchanged drug; fecal: <20%; biliary: minor
Category C
Category C
Antituberculosis Agent
Antituberculosis Agent